Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
Dyadic International, Inc. (AMEX:DIL), a biotechnology
company, announced today that Glenn Nedwin, Ph.D, Dyadic's Chief
Scientific Officer, Executive Vice President and President of Dyadic's
Biosciences Business, will make a presentation at the ThinkEquity
Partners 4th Annual Growth Conference to be held at the Ritz Carlton
Hotel in San Francisco on September 11-14, 2006. Dr. Nedwin's
presentation is scheduled for September 14 at 11:00 a.m. PDT (2 p.m.
EDT).
A simultaneous webcast of the presentation may be accessed by
clicking the webcast link at http://www.dyadic.com. A replay will be
available for 30 days at the same internet address.
Dr. Nedwin plans to discuss the Company's progress in the
development of its technologies for the production of new, better and
more affordable products in its three core business areas:
-- Biorefineries, to communicate the Company's recent advances in
the development of its patented and proprietary enzyme
mixtures to make abundant low cost sugars from agricultural
plant materials (energy crops). Sugars are currently being
used to produce ethanol, plastics and polymers to displace
petroleum in a variety of manufacturing and refining
processes.
-- Biosciences, to provide an update on the Company's progress to
leverage its C1 Host Technology for use in collaboration with
biotech and pharmaceutical companies to enable them to more
efficiently discover, develop and produce new, better and more
affordable human antibodies and other drugs; and
-- Enzymes, to report on the Company's progress in expanding from
its historical textile enzyme business to larger and more
profitable markets such as pulp and paper and animal feed.
About Dyadic
Dyadic International, Inc., based in Jupiter, Florida, with
operations in the United States of America, Hong Kong and mainland
China, Poland and The Netherlands, is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic is
applying its technologies to produce enzymes for use in converting
various agricultural products (e.g. corn) and waste products (e.g.
switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper, animal feed, alcohol, starch, and food and
beverage industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005, and our
subsequent filings with the SEC. Except as required by law, we
expressly disclaim any intent or obligation to update any
forward-looking statements.